|
|
|
Volumn 50, Issue 1287, 2008, Pages 42-43
|
|
Bevacizumab (Avastin) for metastatic breast cancer
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE DERIVATIVE;
BEVACIZUMAB;
CAPECITABINE;
DOCETAXEL;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
EPIRUBICIN;
PACLITAXEL;
TAXANE DERIVATIVE;
TRASTUZUMAB;
ANGIOGENESIS INHIBITOR;
MONOCLONAL ANTIBODY;
ABDOMINAL ABSCESS;
ABDOMINAL PAIN;
BREAST CANCER;
CANCER GROWTH;
CANCER INHIBITION;
CANCER SURVIVAL;
CLINICAL TRIAL;
COLON CANCER;
CONSTIPATION;
DIARRHEA;
DIGESTIVE SYSTEM PERFORATION;
DRUG COST;
DRUG INDUCED HEADACHE;
DRUG MECHANISM;
DRUG RESPONSE;
FATIGUE;
GASTROINTESTINAL HEMORRHAGE;
HAND FOOT SYNDROME;
HEADACHE;
HUMAN;
HYPERTENSION;
INTESTINE PERFORATION;
LUNG HEMORRHAGE;
LUNG NON SMALL CELL CANCER;
METASTASIS;
NAUSEA;
NEUTROPENIA;
PROGRESSION FREE SURVIVAL;
PROTEINURIA;
RETINA MACULA AGE RELATED DEGENERATION;
SHORT SURVEY;
TREATMENT OUTCOME;
VOMITING;
WOUND HEALING IMPAIRMENT;
ARTICLE;
BREAST TUMOR;
ECONOMICS;
FEE;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
BREAST NEOPLASMS;
FEES, PHARMACEUTICAL;
HUMANS;
|
|
EID: 44649126782
PISSN: 0025732X
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
|
Times cited : (3)
|
|
References (7)
|
